NEW
YORK, July 8, 2024 /PRNewswire/ -- The
global oral cancer therapeutics market size is estimated
to grow by USD 1.61 billion from
2024-2028, according to Technavio. The market is estimated to grow
at a CAGR of 10.03% during the forecast
period. Increasing incidence and prevalence of oral
cancer is driving market growth, with a trend
towards increase r and d of new drugs. However, side
effects of chemotherapeutics poses a challenge. Key market
players include Amneal Pharmaceuticals Inc., AstraZeneca Plc,
Bristol Myers Squibb Co., Cipla Inc., Eli Lilly and Co., Endo
International Plc, F. Hoffmann La Roche Ltd., Fresenius SE and Co.
KGaA, GlaxoSmithKline Plc, Intas Pharmaceuticals Ltd., Lupin Ltd.,
Merck and Co. Inc., Pfizer Inc., Sanofi SA, Sun Pharmaceutical
Industries Ltd., Takeda Pharmaceutical Co. Ltd., and Viatris
Inc..
Get a detailed analysis on regions, market
segments, customer landscape, and companies - Click for the
snapshot of this report
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Product (Targeted
therapy and Chemotherapy) and Geography (North America, Europe,
Asia, and Rest of World (ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
Amneal Pharmaceuticals
Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Cipla Inc., Eli
Lilly and Co., Endo International Plc, F. Hoffmann La Roche Ltd.,
Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Intas
Pharmaceuticals Ltd., Lupin Ltd., Merck and Co. Inc., Pfizer Inc.,
Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda
Pharmaceutical Co. Ltd., and Viatris Inc.
|
Key Market Trends Fueling Growth
The oral cancer therapeutics market is witnessing significant
growth due to the rising prevalence of oral cancer and the need for
novel therapeutics for its treatment. While chemotherapy drugs are
currently the primary treatment option, targeted therapies are
gaining attention. For instance, Gliknik Inc.'s biropepimut-S
(GL-0817) is a peptide immunomodulator in clinical trials for
treating squamous cell carcinoma of the oral cavity. Other vendors,
such as Celldex Therapeutics, Merck, and AstraZeneca, are
developing targeted therapies and combination therapies, including
cabozantinib, CDX-3379 and cetuximab, androgen deprivation therapy
and pembrolizumab, and IMFINZI and tremelimumab, respectively.
These therapies are in various stages of clinical trials for
treating advanced head and neck squamous cell carcinomas, including
oral cavity cancers. The focus on developing novel therapeutics and
combination therapies will drive the growth of the oral cancer
therapeutics market during the forecast period.
The Oral Cancer Therapeutics Market is witnessing significant
growth due to increased research by institutions and healthcare
organizations. Patient-centric approaches, telemedicine, and remote
monitoring are trending in oral cancer treatment. The Oral Cancer
Foundation and dental technology developments are playing a crucial
role in early detection and diagnosis. The elderly population is at
a higher risk, with root caries, mouth sores, and loss of appetite
being common symptoms. Side effects like hair loss, nausea, and
vomiting from treatments are concerns. Healthcare infrastructure
development is essential for providing access to biopsies and
imaging tests. Dental caries, smoking, human papillomavirus
infection, and dentures pose risks. Advanced technologies like
clinical trials for squamous cell carcinoma, verrucous carcinoma,
Type 2 diabetes, oral leukoplakia, and erythroplakia are underway.
The global geriatric population's growing footprint and the lack of
dexterity in elderly patients necessitate innovative solutions.
Oral cancer treatments are evolving, with hospitals and clinics,
dentists, and ENT specialists collaborating to improve
care.
Discover 360° analysis of this market. For
complete information, schedule your consultation- Book
Here!
Market Challenges
- Oral cancer therapeutics market growth may be hindered by the
side effects of chemotherapeutics, which are a significant concern
for patients. Common side effects include vomiting, nausea, mouth
sores, joint and muscle aches, paresthesia, flushing,
shortness of breath, urticaria (hives), rash, anaphylactic
reactions, anemia, infection, sterility, secondary malignancies,
diarrhea, ulceration, bleeding, and bone marrow suppression. These
side effects can lead to patient discomfort and non-compliance with
treatment. For instance, platinum-based chemotherapies, such as
carboplatin, may cause hypersensitivity reactions in children.
Taxanes (paclitaxel and docetaxel) can result in mouth sores, joint
and muscle aches, paresthesia, flushing, shortness of breath,
urticaria (hives), rash, and anaphylactic reactions. Alkylating
agents (carboplatin) may lead to anemia, infection, sterility, and
secondary malignancies. Antimetabolites (hydroxyurea and
5-fluorouracil) can cause diarrhea, ulceration, bleeding, and bone
marrow suppression. These side effects may limit the market growth
during the forecast period.
- The Oral Cancer Therapeutics Market faces several challenges.
Inadequate healthcare infrastructure, especially in developing
countries, hinders early detection and treatment. Dental caries and
other oral diseases can mask oral cancer symptoms. The global
geriatric population's expansion increases the risk of oral cancer.
Advanced technologies for oral cancer treatments have a limited
global footprint. Biopsies and imaging tests are essential for
diagnosis but can be invasive and expensive. Risk factors like
smoking, human papillomavirus infection, dentures, and lack of
dexterity complicate treatment. Squamous cell carcinoma and
verrucous carcinoma are common oral cancer types. Clinical trials
for new treatments are ongoing for conditions like Type 2 diabetes,
oral leukoplakia, erythroplakia, and HPV-related cancers. Hospitals
and clinics, dentists, ENT specialists, and other healthcare
providers play crucial roles in Oral Cancer Treatment. Surgery,
radiation therapy, chemotherapy, targeted therapy, minimally
invasive surgeries, and lifestyle modifications are common
treatments. Tobacco consumption, alcohol consumption, and HPV
infection are significant risk factors. Changing lifestyles and
diagnostic techniques, imaging technologies, biomarker testing, and
molecular diagnostics are essential for improving outcomes.
For more insights on driver and
challenges - Download a Sample Report
Segment Overview
This oral cancer therapeutics market report extensively covers
market segmentation by
- Product
- 1.1 Targeted therapy
- 1.2 Chemotherapy
- Geography
- 2.1 North America
- 2.2 Europe
- 2.3 Asia
- 2.4 Rest of World (ROW)
1.1 Targeted therapy- The oral cancer
therapeutics market is experiencing significant growth due to the
increasing number of oral cancer cases worldwide. Key players in
this market include Merck & Co., Inc., Pfizer Inc., and Eli
Lilly and Company. They are investing in research and development
of novel therapies, such as targeted therapies and immunotherapies,
to improve treatment outcomes and patient survival rates.
Additionally, the rising awareness about early detection and
screening is driving market growth. Overall, the oral cancer
therapeutics market is expected to continue expanding in the coming
years.
For more information on market segmentation with
geographical analysis including forecast (2024-2028) and historic
data (2018 - 2022) - Download a Sample Report
Research Analysis
Oral cancer, a type of head and neck cancer, is a significant
global health concern. Treatment options include surgery, radiation
therapy, chemotherapy, targeted therapy, and minimally invasive
surgeries. Tobacco consumption and alcohol use are major risk
factors, while human papillomavirus (HPV) infections and changing
lifestyles are emerging causes. Diagnostic techniques, imaging
technologies, and biomarker testing are essential for early
detection. Molecular diagnostics and geriatric population research
are key areas of focus due to the increasing elderly population.
The Oral Cancer Foundation advocates for awareness and support.
Dental technology developments offer new opportunities for
prevention and treatment. Side effects of oral cancer therapies
include hair loss, mouth sores, and loss of appetite. Root caries
and pearl are less common but significant oral health issues
related to oral cancer treatment. Despite advances, research
institutions and healthcare organizations continue to explore new
treatments and improve patient outcomes.
Market Research Overview
Oral cancer, a type of head and neck cancer, affects the lips,
tongue, floor of the mouth, and other areas in and around the
mouth. Treatment options include surgery, radiation therapy,
chemotherapy, targeted therapy, and minimally invasive surgeries.
Risk factors for oral cancer include tobacco consumption, alcohol
consumption, human papillomavirus infection, and changing
lifestyles. Diagnostic techniques, such as biopsies and imaging
tests, are crucial for early detection. Advanced technologies, such
as molecular diagnostics and biomarker testing, are also playing an
increasingly important role. The geriatric population is
particularly vulnerable due to the global aging population and the
prevalence of dental caries, root caries, and other oral health
issues. Healthcare organizations, research institutions, and
patient-centric approaches are driving innovation in oral cancer
treatment. Telemedicine and remote monitoring offer new
opportunities for access to care. The Oral Cancer Foundation and
dental technology developments are also contributing to advances in
treatment and diagnosis. Side effects of oral cancer treatments,
such as hair loss, mouth sores, loss of appetite, nausea, and
vomiting, can be managed with proper care. Other risk factors, such
as squamous cell carcinoma, verrucous carcinoma, clinical trials,
Type 2 diabetes, oral leukoplakia, and erythroplakia, are also
areas of ongoing research. The lack of dexterity in elderly
patients and the use of dentures can present challenges in
diagnosis and treatment. Hospitals and clinics, dentists, and ENT
specialists are key players in the delivery of oral cancer care.
Smoking and human papillomavirus infection are major causes of oral
cancer, and prevention efforts are crucial for reducing the global
footprint of this disease.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Product
-
- Targeted Therapy
- Chemotherapy
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/oral-cancer-therapeutics-market-size-is-set-to-grow-by-usd-1-61-billion-from-2024-2028--increasing-incidence-and-prevalence-of-oral-cancer-to-boost-the-market-growth-technavio-302189687.html
SOURCE Technavio